Results 91 to 100 of about 36,434 (294)
, 2012 Mutations in the human ether-a-go-go-related gene (hERG) result in long QT syndrome type 2 (LQT2). The hERG gene encodes a K+ channel that contributes to the repolarization of the cardiac action potential.
Gong, Qiuming +3 more
core +1 more source
The light and shadow of senescence and inflammation in cardiovascular pathology and regenerative medicine [PDF]
, 2017 Recent epidemiologic studies evidence a dramatic increase of cardiovascular diseases, especially associated with the aging of the world population. During aging, the progressive impairment of the cardiovascular functions results from the compromised ...
Cavarretta, Elena +9 more
core +4 more sources
hERG potassium channel blockage by scorpion toxin BmKKx2 enhances erythroid differentiation of human leukemia cells K562. [PDF]
PLoS ONE, 2013 The hERG potassium channel can modulate the proliferation of the chronic myelogenous leukemic K562 cells, and its role in the erythroid differentiation of K562 cells still remains unclear.The hERG potassium channel blockage by a new 36-residue scorpion ...
Jian Ma +5 more
doaj +1 more source
American Journal of Physiology. Heart and Circulatory Physiology, 2020 hERG K+ channels are important in cardiac repolarization and their dysfunction causes prolongation of the ventricular action potential, Long QT Syndrome, and arrhythmia.
Y. Shi +13 more
semanticscholar +1 more source
Effects of cariprazine on hERG 1A and hERG 1A/3.1 potassium channels
European Journal of Pharmacology, 2019 Cariprazine is a novel atypical antipsychotic drug that is widely used for the treatment of schizophrenia and bipolar mania/mixed disorder. We used the whole-cell patch-clamp technique to investigate the effects of cariprazine on hERG channels that are stably expressed in HEK cells. Cariprazine inhibited the hERG 1A and hERG 1A/3.1 tail currents at -50
Hong Joon, Lee +3 more
openaire +2 more sources
Concentration–QTc Modeling to Support Clinical Development of Fezolinetant
Clinical Pharmacology in Drug Development, EarlyView.Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment ...
Jace C. Nielsen +6 more
wiley +1 more source
Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations. [PDF]
, 2019 Drug-induced block of the cardiac rapid delayed rectifying potassium current (I Kr), carried by the human ether-a-go-go-related gene (hERG) channel, is the most common cause of acquired long QT syndrome.
Chen, I-Shan +6 more
core +1 more source
Shortening of the Short Refractory Periods in Short QT Syndrome. [PDF]
, 2017 BACKGROUND: Diagnosis of short QT syndrome (SQTS) remains difficult in case of borderline QT values as often found in normal populations. Whether some shortening of refractory periods (RP) may help in differentiating SQTS from normal subjects is unknown.
Cardin, C +10 more
core +3 more sources
Lead optimisation of dehydroemetine for repositioned use in malaria [PDF]
, 2020 Drug repositioning offers an effective alternative to de novo drug design to tackle the urgent need for novel anti-malarial treatments. The anti-amoebic compound, emetine dihydrochloride, has been identified as a potent in-vitro inhibitor of the multi ...
Abubaker, M +8 more
core +3 more sources
Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
PLoS ONE, 2015 Promiscuous inhibition of the human ether-à-go-go-related gene (hERG) potassium channel by drugs poses a major risk for life threatening arrhythmia and costly drug withdrawals.
Fang Du +4 more
doaj +1 more source